PhAST Diagnostics is using AI imaging technology to combat antibiotic resistance. ANtibiotic resistance is a global challenge necessitating the use of new technologies to solve. By combining the power of single-cell imaging and a cloud-based platform, PhAST is enhancing infectious disease diagnostics. Imaging enables the immediate and extension analysis of pathogens, with the information providing clinical decision support for doctors, workflow improvements for hospitals, in addition to accelerating drug development processes for pharmaceutical companies.

PhAST Diagnostics

Founded: 2017
Location: Boston, MA
Employee range: 11 - 50
Funding: $10.6M A Jan 2022
Investors: SV investment, LabCorp, Naver Cloud

Short description:

Drug notes:

Long description:

Jobs: